Go Pro
NASDAQ:SBFM

Sunshine Biopharma Q2 2026 Earnings Report

Sunshine Biopharma logo
$1.15 -0.05 (-4.17%)
Closing price 04:00 PM Eastern
Extended Trading
$1.17 +0.02 (+2.09%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sunshine Biopharma EPS Results

Actual EPS
-$1.15
Consensus EPS
-$1.20
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Sunshine Biopharma Revenue Results

Actual Revenue
$9.26 million
Expected Revenue
$8.70 million
Beat/Miss
Beat by +$563.69 thousand
YoY Revenue Growth
N/A

Sunshine Biopharma Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Sunshine Biopharma Earnings Headlines

Sunshine Biopharma (SBFM) Expected to Post Earnings on Tuesday
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.tc pixel
SBFM Share News Today
See More Sunshine Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sunshine Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sunshine Biopharma and other key companies, straight to your email.

About Sunshine Biopharma

Sunshine Biopharma (NASDAQ:SBFM) is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies. These molecules are engineered to enhance tumor selectivity and minimize cardiotoxicity commonly associated with traditional anthracyclines.

The company is headquartered in Montreal, Canada, and operates research facilities in North America. Sunshine Biopharma collaborates with academic institutions and contract research organizations to conduct preclinical studies and regulatory activities. Leadership is headed by Dr. Bhupinder Kaur Singh, who serves as President and Chief Executive Officer, guiding corporate strategy, research priorities and investor relations.

View Sunshine Biopharma Profile